FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next >>
 
TXT New AI Transparency Minimums Needed: Column
01/10/2023
 
 
TXT FDA, Health Canada Open eSTAR Pilot
01/10/2023
 
 
TXT AdvaMed Recommendations on Consensus Standards
01/10/2023
 
 
TXT NDA/BLA Approval Metrics Take a Hit in 2022
01/10/2023
 
 
TXT CDER Dismisses 26% Drop in 2022 Drug Approvals
01/09/2023
 
 
TXT BioMarin Filing Additional Data for Hemophilia Gene Therapy
01/09/2023
 
 
TXT Troubled Zyno Pays $493K over False Claims
01/09/2023
 
 
TXT Review extension for Krystal Gene Therapy BLA
01/09/2023
 
 
TXT CardiacSense Vital Signs Watch Cleared by FDA
01/09/2023
 
 
TXT Law Extends Product Info Sharing Safe Harbor to Devices
01/06/2023
 
 
TXT Evusheld May Not Neutralize New Covid Variant: FDA
01/06/2023
 
 
TXT FDA Hits Ipsen with Complete Response on Palovarotene
01/06/2023
 
 
TXT Generic Drug Controlled Correspondence Revised Guidance
01/06/2023
 
 
TXT ODT Launches Leadership Modernization Action Plan
01/06/2023
 
 
TXT FDA Delays Toripalimab PDUFA Action Date
01/06/2023
 
 
TXT Cavazzoni Tries to Repair Credibility with New Alzheimer’s OK
01/06/2023
 
 
TXT Lupin Recalls 4 Quinapril Lots
01/05/2023
 
 
TXT FDA Approves Zycosan for Horses with Osteoarthritis
01/05/2023
 
 
TXT Reverse ‘Calif. Consumer Protection Regime’: WLF
01/05/2023
 
 
TXT Genentech’s Lunsumio OK’d for Some Lymphomas
01/05/2023
 
 
TXT REMS Document Technical Conformance Guide
01/05/2023
 
 
TXT Jet Medical, Other Companies, Pay $700,000 in Device Cases
01/05/2023
 
 
TXT Checkpoint Therapeutics BLA for Skin Cancer
01/05/2023
 
 
TXT 5 Observations on Glenmark FDA-483
01/05/2023
 
 
TXT FDA Approves Rozlytrek Companion Diagnostic
01/05/2023
 
 
TXT Group Urges Postponement of Alzheimer’s Drug Decision
01/05/2023
 
 
TXT Build Flexibility into Pubertal Development Guidance: BIO
01/05/2023
 
 
TXT AstraZeneca BLA for RSV Prevention in Infants
01/05/2023
 
 
TXT Medical Device Consensus Standards Database Updated
01/04/2023
 
 
TXT FDA Changes Mifepristone REMS
01/04/2023
 
 
TXT FDA Reforms Included in Year-end Omnibus Bill
01/04/2023
 
 
TXT Accord Healthcare Recalls 2 Daptomycin Products
01/04/2023
 
 
TXT FDA Approves Acer’s Olpruva for Urea Cycle Disorders
01/04/2023
 
 
TXT RoyalVibe Health Refused Inspection: FDA
01/04/2023
 
 
TXT Inspection Issues at Sagent’s Plattsburgh Facility
01/04/2023
 
 
TXT FTC Updates Health Products Compliance Guide
01/04/2023
 
 
TXT CGMP Deviations Found at MD Pharmaceutical Supply
01/04/2023
 
 
TXT FDA Delays PDUFA Action Date for Phathom’s Vonoprazan
01/04/2023
 
 
TXT New Alzheimer’s Drug OK This Week Won’t Do Much for Patients: Article
01/04/2023
 
 
TXT REMS Document Format, Content Guidance
01/04/2023
 
 
TXT Arrow Intra-Aortic Balloon Pump Recall is Class 1
01/04/2023
 
 
TXT Latest Potential Signals of Serious Drug Risks
01/04/2023
 
 
TXT Drug Companies Expected to Hike Prices
01/04/2023
 
 
TXT Vivos Gets Sleep Apnea Device Cleared
01/04/2023
 
 
TXT Consider Oncology Single-Arm Trial Issues: CDER
01/04/2023
 
 
TXT FDA Lifts Partial Hold on Bluebird Bio Lovo-Cel Study
01/04/2023
 
 
TXT Advanced Bionics Paying $12 Million Over False Claims
01/03/2023
 
 
TXT CGMP Deviations at Brazil’s Nortec Quimica
01/03/2023
 
 
TXT FDA States Plan B One-Step Does Not Cause an Abortion
01/03/2023
 
 
TXT Court Enters Consent Decree Against Oklahoma Compounder
01/03/2023
 
 
TXT M11 Clinical Electronic Structured Protocol
01/03/2023
 
 
TXT Drug Risks and Benefits in CSL Communications
01/03/2023
 
 
TXT ‘Objectionable Conditions’ at Clinical Investigation Site
01/03/2023
 
 
TXT Spending Bill Reverses Some FDA Court Losses: Attorneys
01/03/2023
 
 
TXT FDA Pushing Naloxone OTC Switch: Attorney
01/03/2023
 
 
TXT Hypertension Labeling for Cardio Claims Guidance
01/03/2023
 
 
TXT FDA Gets $226 Million Spending Boost in Budget Bill
01/03/2023
 
 
TXT FDA Grants Ardelyx’ Xphozah Appeal
01/03/2023
 
 
TXT FDA Discusses 2 New Trilogy Ventilator Issues
01/03/2023
 
 
TXT FDA Needs More Global Help Against Crime: Hermsen
01/03/2023
 
 
TXT Reactions to Aduhelm Report Blast FDA Closeness to Industry
01/03/2023
 
 
TXT Providence Medical Tech Cavux Facet Device Cleared
12/16/2022
 
 
TXT FDA OK’s Ferring’s Bladder Cancer Gene Therapy
12/16/2022
 
 
TXT Panel to Examine Ongoing Covid Vaccine Modifications
12/16/2022
 
 
TXT Contractor Conflict-of Interest Bill Passes Congress
12/16/2022
 
 
TXT Aurigene Ditches Psoriasis Drug Candidate
12/16/2022
 
 
TXT FDA Updates CRL Guidance Performance Goals
12/15/2022
 
 
TXT Comments on Immune-Mediated Adverse Reaction Guidance
12/15/2022
 
 
TXT Independent FDA Needed to Stop Political Meddling: GAO
12/15/2022
 
 
TXT Draft Guide on Pulmonary Tuberculosis Drugs
12/15/2022
 
 
TXT Draft Inspection Refusal Guidance
12/15/2022
 
 
TXT FDA Stem Cell Therapy Regulation at Risk: Attorneys
12/15/2022
 
 
TXT States Pushing for Canadian Drug Imports: Report
12/14/2022
 
 
TXT Harmonize Innovative Manufacturing Regulation: PhRMA
12/14/2022
 
 
TXT AdvaMed Supports Breakthrough Device Guidance Updates
12/14/2022
 
 
TXT VALID Could Hurt Home Sample Testing: Attorneys
12/14/2022
 
 
TXT Former NECC Ops Director Sentenced to 5 Months in Jail
12/14/2022
 
 
TXT FDA Panel Thumbs Down on Heart Failure Drug
12/14/2022
 
 
TXT FDA Accepts NDA for Eye Dilating Combo Product
12/13/2022
 
 
TXT $2.25 mil. RWD Funding Opportunity
12/13/2022
 
 
TXT CGMP Deviations Seen in Centrient Inspection
12/13/2022
 
 
TXT Clinicians Need Refresher on Clinical Trial Statistics: Survey
12/13/2022
 
 
TXT What’s Behind the New LASIK Guidance?
12/13/2022
 
 
TXT Assign TE Codes for All Approved Drugs: Study
12/13/2022
 
 
TXT Change Antibiotic Development Incentives: Study
12/13/2022
 
 
TXT Moderna/Merck Cancer Vaccine Meets Endpoint
12/13/2022
 
 
TXT Doc Group Wants FDA Probe of Musk’s Neuralink
12/13/2022
 
 
TXT Smiths Device Correction on CADD Infusion System
12/12/2022
 
 
TXT CVM Sees 1% Decrease in Food Animal Antimicrobial Use
12/12/2022
 
 
TXT Academics Urge FDA to Simplify Breast Density Notifications
12/12/2022
 
 
TXT DoJ Indictment on Unapproved Drugs
12/12/2022
 
 
TXT Panel Meeting to Discuss Isotretinoin iPLEDGE REMS Program
12/12/2022
 
 
TXT FDA Hits 2 QuVA Pharma Facilities with 483s
12/12/2022
 
 
TXT Green Pharmaceuticals’ SnoreStop ‘Adulterated’: FDA
12/11/2022
 
 
TXT Empowered Diagnostics Unapproved Covid Tests
12/11/2022
 
 
TXT FDA Will Review Pfizer Etrasimod NDA
12/11/2022
 
 
TXT Address Prescription Adderall Shortage: Spanberger
12/11/2022
 
 
TXT Academics Urge Tougher FDA Stance on Accelerated NDAs
12/09/2022
 
 
TXT Device Voluntary Malfunction Summary Reporting Guide
12/09/2022
 
 
TXT Remel Recalls Thermo Scientific Sensititre Plates
12/09/2022
 
 
<< Prev  15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving